Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Change City

(BPT) - Kristen Beatty’s 78-year-old father, Ray, was diagnosed with Alzheimer’s about 10 years ago. Since then, he has developed a sense of paranoia, insomnia and the delusion that people are stealing from him. Though Beatty and her brother constantly reassure their father to allay his fears, the daily struggle can take its toll. Beatty’s mother, Sue, had previously cared for Ray for about five years. In 2012, Sue died unexpectedly of a heart attack, or as Beatty puts it, she died of a broken heart.

“She was exhausted from the constant care and the pressure that came with it,” Beatty said. “She was eating super healthy, walking every day and taking very good care of herself, so I truly believe it was the stress. My brother and I feel guilty because we could have supported her better, but she wouldn’t ask for help. She wouldn’t consider moving him to a facility or going to support groups.”

The stress and the pressure Beatty’s mother faced is not unlike the experiences of millions of other Alzheimer’s caregivers around the nation, who primarily care for people with the disease because of their desire to keep their family member at home, their proximity to the person with dementia or their perceived obligation — all pressures that can lead to harsh consequences for caregivers.

For example, more than one in three caregivers for people with Alzheimer’s or other dementias report their health has gotten worse due to care responsibilities, compared with one out of five caregivers for older people without dementia. And depression and anxiety are more common among dementia caregivers than among people providing care for individuals with certain other conditions.

These findings are part of the Alzheimer’s Association "2017 Alzheimer’s Disease Facts and Figures report," released recently. The report analyzes new research about cost, prevalence, incidence, caregiving, and mortality and morbidity. The report found a dramatic surge in deaths from Alzheimer’s — the only cause of death among the top 10 in America that cannot be prevented, cured or even slowed. Meanwhile, deaths from other major causes are decreasing. Between 2000 and 2014, deaths from heart disease decreased 14 percent, but deaths from Alzheimer’s increased 89 percent.

Another finding was the growing cost burden of Alzheimer’s. For the first time ever, it now costs over a quarter of a trillion dollars ($259 billion) annually to care for individuals living with Alzheimer’s and other dementias in the United States — $56 billion of which is coming right from individuals’ pockets. According to the report, out-of-pocket costs for people affected by Alzheimer’s are startlingly high, despite support from Medicare and Medicaid. In fact, annual per-person payments for seniors with Alzheimer’s and other dementias are almost five times higher ($10,315) than those for seniors without these conditions ($2,232).

According to Beth Kallmyer, vice president of constituent services for the Alzheimer’s Association, providing ongoing support for the estimated 5.5 million Americans living with Alzheimer’s will need to remain a national policy priority moving forward, as the population at risk for Alzheimer’s is projected to nearly double from 48 million to 88 million by 2050.

“As the number of people with Alzheimer’s continues to grow, so does the impact and cost of providing care to our health system and the millions of unpaid caregivers,” Kallmyer said. “While we’ve seen increases in federal research funding and access to critical care planning and support services, there’s still an urgent need to expand options and support for family-centered and community care and to fund more research that can bring us closer to effective treatment options and, ultimately, a cure.”

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.